CMPI · Checkmate Pharmaceuticals Inc.
Acquired Company
Regeneron completed its acquisition of Checkmate Pharmaceuticals on 5/31/2022 for $10.50 per share in cash, representing a total transaction value of approximately $250 million.
Checkmate Pharmaceuticals, Inc. operates as a biotechnology company. The Company discovers and develops novel approaches for cancer immunotherapy such as immuno-oncology. Checkmate Pharmaceuticals serves patients worldwide.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$10.50
Open
$10.50
Volume
N/A
Day Range
$10.50 - $10.50
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
N/A
Institutional Own.
N/A
Qtr Updated
Jun 30th 2024